Tenormin I.V. Related Published Studies
Well-designed clinical trials related to Tenormin I.V. (Atenolol)
Identifying iatrogenic depression using confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in patients prescribed a verapamil-sustained-release-led or atenolol-led hypertension treatment strategy. [2011.11.29]
[Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome]. [2011.06]
Comparison of the effects of ivabradine and atenolol on heart rate and echocardiographic variables of left heart function in healthy cats. [2011.05]
Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension. [2011.01]
beta(1)-Adrenergic receptor gene polymorphisms and the acute response to atenolol in healthy young Japanese subjects. [2011]
Atenolol exposure and risk for development of adverse metabolic effects: a pilot study. [2010.09]
Attenuation of adenosine-induced myocardial perfusion heterogeneity by atenolol and other cardioselective beta-adrenoceptor blockers: a crossover myocardial perfusion imaging study. [2010.07]
Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. [2010.06]
Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. [2010.04]
Cardiovascular drugs in human mechanical nociception: digoxin, amlodipine, propranolol, pindolol and atenolol. [2010.03]
Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. [2010.01]
A randomized, comparative, multicentric evaluation of atenolol/amlodipine combination with atenolol alone in essential hypertensive patients. [2010.01]
Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. [2009.12]
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order. [2009.11]
Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian cardiac outcome trial substudy. [2009.10]
The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA). [2009.08]
Effects of losartan on fibrinolytic parameters and von Willebrand factor in Chinese subjects with hypertension: a comparative study versus atenolol. [2009.05]
Efficacy of exercise, losartan, enalapril, atenolol and rilmenidine in subjects with blood pressure hyperreactivity at treadmill stress test and left ventricular hypertrophy. [2009.04]
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. [2008.08]
The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. [2008.07]
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. [2008.02]
Short-term effects of cilazapril and atenolol on P-wave dispersion in patients with hypertension. [2008.02]
Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. [2007.10]
Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. [2007.05]
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. [2007.05]
The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. [2007.01]
Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy results from the swedish irbesartan left ventricular hypertrophy investigation vs atenolol (SILVHIA). Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). [2006.09]
Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. [2006.09]
Effect of rifampicin on the pharmacokinetics of atenolol. [2006.06]
How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. [2006.06]
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. [2006.03]
Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. [2006.02]
Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. [2006.02]
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. [2006]
Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). [2006]
Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? [2005.12]
Effect of itraconazole on the pharmacokinetics of atenolol. [2005.12]
Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. [2005.12]
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. [2005.12]
Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. [2005.11]
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. [2005.09.10]
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. [2005.09.06]
Survival times in dogs with severe subvalvular aortic stenosis treated with balloon valvuloplasty or atenolol. [2005.08.01]
Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. [2005.08]
Effects of orange juice on the pharmacokinetics of atenolol. [2005.07]
Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: an echoreflectivity study. [2005.06]
[Metoprolol and atenolol in mild-to-moderate chronic heart failure: comparative study] [2005.05]
Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). [2005.05]
Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. [2005.05]
Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial. [2005.04]
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. [2005.04]
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. [2005.03]
Biopharmaceutical evaluation of oral tablet Atenolol (100 and 50 mg) on local population. [2005.01]
Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. [2005]
A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients. [2005]
Acute hemodynamic effects of amlodipine 15 days after a myocardial infarction in normotensive patients treated with atenolol. [1997.04]
[Atenolol i.v. in the acute phase of AMI: the indications, contraindications and interactions with thrombolytic drugs in the GISSI-2 study. The GISSI-2 Researchers. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico] [1995.03]
[The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus] [1991.04]
Comparative effects of atenolol and cicloprolol on cardiac performance in coronary heart disease. [1989.01]
Beta 1-adrenoceptor selectivity of single oral doses of bisoprolol and atenolol. [1988.09]
Well-designed clinical trials possibly related to Tenormin I.V. (Atenolol)
Acute effects of ivabradine on dynamic obstruction of the left ventricular
outflow tract in cats with preclinical hypertrophic cardiomyopathy. [2014]
Repeated melatonin supplementation improves sleep in hypertensive patients
treated with beta-blockers: a randomized controlled trial. [2012]
Comparison of risk factor reduction and tolerability of a full-dose polypill
(with potassium) versus low-dose polypill (polycap) in individuals at high risk
of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2)
investigators. [2012]
Visit-to-visit blood pressure variability, carotid atherosclerosis, and
cardiovascular events in the European Lacidipine Study on Atherosclerosis. [2012]
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study. [2011.04]
Responses of the ambulatory arterial stiffness index and other measures of arterial function to antihypertensive drugs. [2011.04]
Racial differences in incident heart failure during antihypertensive therapy. [2011.03]
Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). [2011.03]
Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension. [2011.02]
Importance of blood pressure control in left ventricular mass regression. [2010.11]
Cardiac vagal withdrawal and reactivation during repeated rest-exercise transitions. [2010.11]
Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). [2010.10.01]
Brain function, cognition, and the blood pressure response to pharmacological treatment. [2010.09]
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. [2010.09]
Interaction of hyperthermia and heart rate on stroke volume during prolonged exercise. [2010.09]
Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. [2010.08]
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. [2010.08]
Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. [2010.05]
Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. [2010.04.01]
Effects of beta-blockers on glucose and lipid metabolism. [2010.03]
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. [2010.02]
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. [2010.01]
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers. [2010]
How to avoid discontinuation of antihypertensive treatment: The experience in Sao Paulo, Brazil. [2010]
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study. [2009.12]
[Echocardiography of left ventricular mass in patients with essential hypertension] [2009.11.02]
Systolic blood pressure and subjective well-being in patients with coronary artery disease. [2009.11]
Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study. [2009.11]
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). [2009.09.22]
Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). [2009.09]
Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. [2009.08.18]
Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. [2009.08]
Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy. [2009.08]
Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. [2009.08]
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension. [2009.07]
Coronary heart disease benefits from blood pressure and lipid-lowering. [2009.06.26]
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. [2009.06]
Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients. [2009.05]
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). [2009.04.14]
Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy. [2009.04]
Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. [2009.04]
|
